Clinical trial Recruiting at 16 sites Phase 3 Interventional Ages 15 to 45 Women only

Brexanolone therapy for moms with postpartum depression

Official title: A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression

Run by Lipocine Inc. · NCT07822321 · Data updated 2026-11-12

This trial tests LPCN 1154A against placebo to see if it can help reduce depression symptoms in women with severe postpartum depression.

Quick facts

PhasePhase 3
Study typeInterventional
Ages15 Years to 45 Years
SexWomen only
Enrollment120 (estimated)
SponsorLipocine Inc.
Industry-sponsored
Locations16 sites (Tucson, Arizona and 15 other locations)
StatusRecruiting
StartedSeptember 2026
Main results expectedAugust 2027
Study endsSeptember 2027
Registry record updatedSeptember 16, 2026
Trial IDNCT07822321 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women up to 45 years old with severe postpartum depression within 18 months after birth and a high HAM-D score, who do not have bipolar, schizophrenia, schizoaffective disorder, active psychosis, recent seizures, or a history of suicidal behavior in the current episode.

Probably not a fit

Patients with non-severe depression, alternative etiologies of mood disorder, certain psychiatric histories, active psychosis, recent seizures, or those outside the 18-month postpartum window may not benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3 interventional trial evaluating LPCN 1154A as a potential treatment for severe postpartum depression. Participants are adult women up to 45 years old who developed depression around the time of delivery and are within 18 months postpartum, with a high HAM-D score. The study compares LPCN 1154A to placebo to assess efficacy and tolerability, including side effects. Key exclusion criteria include certain psychiatric histories and active psychosis or recent seizure. The trial is sponsored by Lipocine Inc. and conducted at three Lipocine investigational sites in Arizona and California.

Why it matters

Potential benefit: If successful, LPCN 1154A could provide a new treatment option for women with severe postpartum depression and help improve mood and functioning.

How similar studies have gone: Previous trials of similar neuroactive agents in postpartum depression have shown mixed results; this study explores a novel formulation in a Phase 3 setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
Key Inclusion Criteria:

* Are female between 15 and 45 years of age, inclusive;
* Have had a depressive episode that began no earlier than second trimester and no later than the first 4 weeks following delivery
* Are \< 18 months postpartum at Screening
* Hamilton Depression Rating Scale (HAM-D) 17-item score indicative of severe depression

Key Exclusion Criteria:

* Have a history of bipolar disorder, schizophrenia or schizoaffective disorder
* Are currently experiencing active psychosis per Investigator assessment
* Have a history of suicidal behavior associated with the current depressive episode
* Have a history of seizure within six months of Screening

Where it's running

  • Lipocine Investigational Site
    Tucson, Arizona, United States
    Recruiting
  • Lipocine Investigational Site
    Canoga Park, California, United States
    Recruiting
  • Lipocine Investigational Site
    Walnut Creek, California, United States
    Recruiting
  • Lipocine Investigational Site
    Aurora, Colorado, United States
    Recruiting
  • Lipocine Investigational Site
    Decatur, Georgia, United States
    Recruiting
  • Lipocine Investigational Site
    Idaho Falls, Idaho, United States
    Recruiting
Show 10 more locations
  • Lipocine Investigational Site
    Chicago, Illinois, United States
    Recruiting
  • Lipocine Investigational Site
    New Orleans, Louisiana, United States
    Recruiting
  • Lipocine Investigational Site
    Las Vegas, Nevada, United States
    Recruiting
  • Lipocine Investigational Site
    Princeton, New Jersey, United States
    Recruiting
  • Lipocine Investigational Site
    Manhattan, New York, United States
    Recruiting
  • Lipocine Investigational Site
    Chapel Hill, North Carolina, United States
    Recruiting
  • Lipocine Investigational Site
    Plano, Texas, United States
    Recruiting
  • Lipocine Investigational Site
    Richardson, Texas, United States
    Recruiting
  • Lipocine Investigational Site
    Clinton, Utah, United States
    Recruiting
  • Lipocine Investigational Site
    Orem, Utah, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.